ImmunoGen, Inc. Announces Webcast of Panel Session at the 2007 RBC Capital Markets Healthcare Conference
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Dec. 6, 2007--ImmunoGen, Inc. (Nasdaq: IMGN) today announced that Mitchel Sayare, PhD., Chairman and CEO of the Company, will participate on the panel, Antibody Leaders and Next Generation Technologies, at the 2007 RBC Capital Markets Healthcare Conference. This 55-minute panel session will begin at 8:00 am EST on Thursday, December 13, 2007, and will be webcast live. The Conference will take place at the Westin New York at Times Square hotel in New York City
About ImmunoGen, Inc.
ImmunoGen, Inc. develops targeted anticancer biopharmaceuticals. The Company's proprietary Tumor-Activated Prodrug (TAP) technology uses tumor-targeting antibodies to deliver a potent cell-killing agent specifically to cancer cells. Two TAP compounds wholly owned by ImmunoGen are in clinical testing - IMGN901 (huN901-DM1) and IMGN242 (huC242-DM4). Three TAP compounds are in clinical testing through ImmunoGen's collaborations with other companies - AVE9633 and SAR3419, in development by sanofi-aventis, and T-DM1 (trastuzumab-DM1), in development by Genentech. Additionally, the naked antibody compound, AVE1642, is in development through the Company's collaboration with sanofi-aventis. Multiple compounds are in research/preclinical development through ImmunoGen's collaborations and internal programs.
CONTACT:
Investors
ImmunoGen, Inc.
Carol Hausner, 617-995-2500
Executive Director, Investor Relations and Corporate Communications
info@immunogen.com
